Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Martin Stevens

Ann Arbor, MI Medical Doctor

CMS profile 1311407

306 Montgomery Ave, Ann Arbor, MI 48103

Open in the dashboard

General payments

$445,725

446 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Martin Stevens of Ann Arbor, MI is reported in the CMS Open Payments database as having received $445,725 across 446 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $96,756 70
2021 General $101,097 58
2020 General $70,076 104
2019 General $177,796 214

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Martin Stevens
  • Michigan median
  • Middle half of Michigan
  • National median

In program year 2025, general payments to Martin Stevens were reported at $0. Among 33,118 Michigan profiles paid that year, the median was $162 and the middle half received between $49 and $568.

Show as a table
Year Martin Stevens Michigan median Middle half National median
2019 $177,796 $153 $47–$580 $163
2020 $70,076 $108 $35–$342 $114
2021 $101,097 $124 $35–$428 $132
2022 $96,756 $142 $43–$509 $149
2023 $0 $150 $46–$530 $160
2024 $0 $157 $47–$545 $164
2025 $0 $162 $49–$568 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Sanofi-Aventis U.S. LLC $382,256 383 payments
  2. Novo Nordisk Inc $63,470 63 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $402,555 191 payments
  2. Travel and Lodging $36,330 178 payments
  3. Food and Beverage $4,800 75 payments
  4. Consulting Fee $2,040 2 payments
Products named General payments · program years 2019–2022
  1. SOLIQUA 100/33 Endocrine & Metabolic Diseases $185,802 121 payments
  2. SOLIQUA 100/33 Endocrinology $68,516 102 payments
  3. SOLIQUA 100/33 Diabetes $60,117 75 payments
  4. TOUJEO Diabetes $56,249 78 payments
  5. Ozempic $31,556 31 payments
  6. Tresiba $18,491 19 payments
  7. Xultophy 100/3.6 $11,382 11 payments
  8. TOUJEO Endocrine & Metabolic Diseases $10,011 5 payments
  9. TOUJEO Endocrinology $2,600 3 payments
  10. RYBELSUS $2,040 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

446 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record